Is ERAS Worth Buying in 2026?

Erasca, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-23

Here’s whether Erasca, Inc. Common Stock (ERAS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+6.00% over 10 days); RSI 48 — healthy momentum range; strong 1-year return of +1075.3%; 3-month momentum positive (+56.9%). Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.74x 30d avg). Currently 27.4% off its 52-week high. Score: +4/7.

Ready to act on this? 📈 Trade on Webull

ERAS is holding above its long-term 200-day MA ($12.09) but has slipped below the 50-day MA ($17.66), pointing to short-term weakness in an otherwise intact trend. An RSI of 48.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +1075.3% compares to +20.5% for SPY (beat the market by 1054.8%). The current 27.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $117,533 today
vs. S&P 500 (SPY) — same period beat market by 1054.8%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($12.09)
Above 50-day MA ($17.66)
RSI(14) neutral zone (30–70) — currently 48.0
Positive return (+1075.3%)
!Within 10% of period high (−27.4%)
Period Range $17.63
$1.33 $24.28
RSI (14) 48.0
0 · OversoldOverbought · 100

Key Metrics

Price$17.63
Period Return+1075.3%
Period High$24.28
Period Low$1.33
Drawdown−27.4%
MA-50$17.66
MA-200$12.09
RSI (14)48.0
Avg Volume (30d)3.9M
vs. SPYbeat by 1054.8%
Return Rank#1 of 999

Trade ERAS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers